ARCT Arcturus Therapeutics Holdings Inc

Price (delayed)

$21.02

Market cap

$555.33M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$7.53

Enterprise value

$303.2M

Founded in 2013 and based in San Diego, California, Arcturus Therapeutics Holdings Inc. is a clinical-stage mRNA medicines and vaccines company with enabling technologies: (i) LUNAR® lipid-mediated delivery, (ii) STARR™ ...

Highlights
The revenue has surged by 72% year-on-year and by 25% since the previous quarter
Arcturus Therapeutics Holdings's gross profit has surged by 72% YoY and by 25% QoQ
The net income has dropped by 67% year-on-year but it is up by 2.5% since the previous quarter
The company's EPS has shrunk by 51% YoY but it rose by 2.7% QoQ
ARCT's quick ratio has dropped by 66% year-on-year and by 20% since the previous quarter
ARCT's equity is down by 48% year-on-year and by 19% since the previous quarter

Key stats

What are the main financial stats of ARCT
Market
Shares outstanding
26.42M
Market cap
$555.33M
Enterprise value
$303.2M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
3
Price to sales (P/S)
35.82
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
19.59
Earnings
Revenue
$15.48M
EBIT
-$196.37M
EBITDA
-$195.26M
Free cash flow
-$146.53M
Per share
EPS
-$7.53
Free cash flow per share
-$5.56
Book value per share
$7
Revenue per share
$0.59
TBVPS
$12.97
Balance sheet
Total assets
$341.99M
Total liabilities
$157.24M
Debt
$67.55M
Equity
$184.75M
Working capital
$219.7M
Liquidity
Debt to equity
0.37
Current ratio
3.05
Quick ratio
3.01
Net debt/EBITDA
1.29
Margins
EBITDA margin
-1,261.7%
Gross margin
100%
Net margin
-1,282.6%
Operating margin
-1,263.7%
Efficiency
Return on assets
-49.1%
Return on equity
-81.2%
Return on invested capital
N/A
Return on capital employed
-83.7%
Return on sales
-1,268.9%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ARCT stock price

How has the Arcturus Therapeutics Holdings stock price performed over time
Intraday
-5.02%
1 week
20.32%
1 month
10.28%
1 year
-57.36%
YTD
-43.2%
QTD
33.55%

Financial performance

How have Arcturus Therapeutics Holdings's revenue and profit performed over time
Revenue
$15.48M
Gross profit
$15.48M
Operating income
-$195.57M
Net income
-$198.5M
Gross margin
100%
Net margin
-1,282.6%
The revenue has surged by 72% year-on-year and by 25% since the previous quarter
Arcturus Therapeutics Holdings's gross profit has surged by 72% YoY and by 25% QoQ
The net income has dropped by 67% year-on-year but it is up by 2.5% since the previous quarter
Arcturus Therapeutics Holdings's operating income has shrunk by 63% YoY but it has increased by 3.6% QoQ

Growth

What is Arcturus Therapeutics Holdings's growth rate over time

Valuation

What is Arcturus Therapeutics Holdings stock price valuation
P/E
N/A
P/B
3
P/S
35.82
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
19.59
The company's EPS has shrunk by 51% YoY but it rose by 2.7% QoQ
ARCT's equity is down by 48% year-on-year and by 19% since the previous quarter
ARCT's P/B is 21% lower than its last 4 quarters average of 4.0
The revenue has surged by 72% year-on-year and by 25% since the previous quarter
ARCT's price to sales (P/S) is 59% lower than its last 4 quarters average of 92.5

Efficiency

How efficient is Arcturus Therapeutics Holdings business performance
The company's return on equity has shrunk by 89% YoY and by 14% QoQ
The ROA has decreased by 48% YoY and by 6% QoQ
The company's return on sales rose by 22% QoQ and by 3.1% YoY

Dividends

What is ARCT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ARCT.

Financial health

How did Arcturus Therapeutics Holdings financials performed over time
Arcturus Therapeutics Holdings's total assets is 117% higher than its total liabilities
ARCT's quick ratio has dropped by 66% year-on-year and by 20% since the previous quarter
ARCT's current ratio has shrunk by 65% YoY and by 20% QoQ
Arcturus Therapeutics Holdings's debt is 63% lower than its equity
The debt to equity has soared by 106% YoY and by 23% from the previous quarter
ARCT's equity is down by 48% year-on-year and by 19% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.